The outcomes of the Chinese phase 3 NOTABLE trial that demonstrated across 92 patients with KRAS-wildtype unresectable and/or metastatic pancreatic cancer a significant improvement in the primary endpoint of overall survival at one (27% → 44%) and three (3% → 14%) years with the addition of the anti-EGFR monoclonal antibody nimotuzumab to gemcitabine. | Qin, ASCO 2022


Popular Posts